Filter by:

Reset Filter
  • Life Sciences
Showing 1 - 12 of 37
Case

Value Drug Company v. Takeda Pharmaceuticals U.S.A. Inc. et al.

Laurence Baker testified during a rare antitrust trial centering on the allegation that a brand manufacturer conspired with three generics to allocate the market for gout medication colchicine.

Case

In re Novartis and Par Antitrust Litigation

Novartis reached settlements with plaintiffs in this reverse payment matter.

Case

Amgen Inc.’s Acquisition of Horizon Therapeutics plc

The FTC approves Amgen’s $28B purchase of Horizon.

Case

In re HIV Antitrust Litigation

The jury found in favor of the defense concluding, consistent with Dr. Saravia’s testimony, that the settlement contained no payment for delay.

Case

Federal Trade Commission v. 1-800 Contacts

The Second Circuit Court of Appeals overturned an FTC decision regarding trademark enforcement against online competitors.

Case

Alleged Failure to Disclose Drug Safety Issues

Cornerstone Research was retained by a pharmaceutical company facing securities litigation after it withdrew a drug from the market because of safety concerns.

Case

ICC Arbitration Involving Commercially Reasonable Efforts to Develop and Commercialize a Drug

An ICC arbitration tribunal determined that the claimant did not materially breach its license agreement with the respondent, leaving the agreement in full effect.

Case

In re Niaspan Antitrust Litigation

The judge denied class certification in this pharmaceutical pay-for-delay multidistrict litigation.

Case

In re Intuniv Antitrust Litigation

The judge denied class certification in this pharmaceutical pay-for-delay case brought by a class of indirect purchasers.

Case

Cigna’s Acquisition of Express Scripts

The parties completed a $67 billion merger after receiving clearance from the U.S. Department of Justice and state departments of insurance.

Case

Hsu et al. v. Puma Biotechnology Inc. et al.

Positive jury verdict in rare securities class action trial.

Case

Product Hopping

Pharmaceutical manufacturers have been accused of engaging in product hopping by introducing modified versions of branded drugs nearing patent expiry while simultaneously withdrawing the older drugs to hinder generic substitution.

How can we help you?

If you are looking for additional case experience examples, contact us.